Trump's fertility care initiative: A step forward or a missed opportunity?

'Has the price for IVF gone down yet?' 'When will national insurance coverage for IVF start?'

These questions are increasingly common in my fertility practice in the United States following the recent announcement from the White House regarding discounts on in vitro fertilisation (IVF) medications and insurance coverage for fertility treatment (see BioNews 1311). Many believe this initiative will result in a substantial decrease in IVF costs, either through enhanced insurance coverage or direct federal funding. However, the actual impact of these policy announcements is uncertain and will likely be less significant than the general public anticipates.

Access to healthcare in the USA is a critical issue, especially evident within fertility medicine. In my practice in Southern Louisiana, I see this play out daily. Much of my time with patients is devoted to navigating barriers that seem designed to prevent effective and evidence-based fertility care. Throughout the evolution of the field of fertility medicine within the landscape of the American Healthcare system, fertility treatment has been inappropriately viewed as elective or discretionary rather than essential reproductive healthcare. As a result, a complex web of systemic inequalities, financial burdens, geographic disparities, and legal constraints makes accessing treatment for infertility difficult or impossible for many affected patients.

Direct financial burden remains the most discussed obstacle to accessing care, but this is only part of the story. Systemic deficiencies inherent to employer-based health insurance coverage, typical in the USA, are inextricably linked with financial obstacles to accessing fertility treatment like IVF. The cost of one treatment cycle can range from $15,000 to $30,000, depending on factors like age and diagnosis, which can influence the cost per cycle and the number of cycles needed to achieve pregnancy.

This contrasts with other types of routine medical care and surgical procedures, where charges are typically much higher than those for IVF, but the cost to the patient is much lower after the insurance company pays their portion. When insurance plans are not required to include coverage for fertility treatment, individuals are left to shoulder the financial burden alone.

Availability of insurance coverage for fertility treatments in the USA varies significantly depending on location, employer, and insurance provider. While some states have implemented mandates requiring employers offer fertility coverage, most employer-sponsored insurance plans have no fertility benefits. Medicaid, our government-administered health care program for low-income individuals, is generally not subject to mandates and has almost no infrastructure to provide fertility coverage. This patchwork leaves the vast majority of our population without coverage, keeping infertility treatment unaffordable for countless individuals.

The executive initiative released in October attempts to address both financial and systemic barriers to fertility care. First, it describes a new drug pricing agreement with the pharmaceutical company EMD Serono, including discounts up to 84 percent on certain IVF medications through the forthcoming Trump RX website, launching in 2026, and select specialty pharmacies. Second, it provides guidance regarding employer-based fertility benefit programs. The administration has framed this initiative as a breakthrough for affordability in fertility care. However, many in my field remain sceptical that these actions will improve access to treatment.

Specialised medications essential for successful IVF represent a small but significant portion of the expense of treatment, even for those with insurance coverage. The Trump RX discount applies to three such medications: Gonal-F, Ovidrel, and Cetrotide. This discount program mimics existing discount initiatives available through select fertility programs and specialty pharmacies. Depending on the quantity of medications purchased, the Trump RX discount could represent potential savings up to $2200 per IVF cycle, a discount which will likely be somewhat greater than any currently offered for these medications.

However, this discount program only includes these three medications when purchased together, and most treatment protocols require additional medications that are not included in this bundle. While this action is meaningful and may prompt other specialty fertility pharmacies to increase existing discounts or add new programs, this alone will not lessen the financial burden enough to remove the barrier for those unable to access fertility care due to cost.

The second portion of the initiative addresses employer-provided insurance coverage for fertility treatment. Importantly, this is not a mandate for fertility coverage, as many had hoped, and does not offer subsidies or tax benefits for participating employers. It only clarified that employers can voluntarily offer fertility benefits through a mechanism separate from major medical coverage called 'excepted benefits'.

Excepted benefit coverage will allow employers to offer support for fertility treatment through two possible mechanisms: a standalone fertility benefit separate from traditional major medical plans or a reimbursement for fertility care up to $2150 annually through a health reimbursement arrangement (HRA).

Traditionally, fertility benefits, even those provided by fertility-specialised third parties, are offered through major medical insurance plans, which are subject to a multitude of regulations and consumer protections. If fertility coverage is offered through 'excepted benefits', these protections will not apply. Additionally, this structure may allow employers broad discretion to design benefits based on religion or ideology, potentially excluding certain populations from access. Overall, this measure allows employers to voluntarily participate in a less regulated and lower-impact form of support for fertility treatment, but is unlikely to create pathways to care for populations currently facing the most significant barriers to access.

In the USA in recent years, fertility care has received more national attention than ever before, with politicians and legislators racing to declare their support for IVF. However, legislative efforts addressing the affordability crisis in fertility medicine from both major parties have struggled to garner enough support to pass. Senators Tammy Duckworth, Patty Murray, and Cory Booker have repeatedly introduced bills without success, attempting to safeguard and expand access to fertility treatment, including the 'Right to IVF Act', which would establish a statutory right to IVF and create significantly more coverage for all Americans, including military personnel (see BioNews 1243).

Additionally, Representative Mike Lawler's proposed legislation to create a tax credit for IVF has not gained significant traction in Congress, and critics argue this would only help individuals with sufficient income to benefit from the tax relief after paying for treatment upfront. Despite increased attention and legislative efforts in Congress, measurable changes in the affordability of fertility treatment are yet to come.

As a provider, I'm grateful that fertility treatment has become a major part of our national conversation in the USA. Public dialogue around affordability and insurance coverage signals that a federal mandate or universal fertility coverage would be met with broad approval among Americans. While this initiative falls short of Mr Trump's campaign promise for universal coverage (see BioNews 1254), it signifies an exciting change as it represents the first time a US administration has directly addressed fertility treatment access and affordability.

Practising fertility medicine in Louisiana, a state where our population has fewer resources and little to no insurance coverage for fertility treatment, I regularly see patients desperate to conceive but unable to afford the recommended treatment. Through discussions with colleagues across the country, I know our situation is not unique and is reflective of access deficiencies throughout the USA.

Despite our hope that action by the Trump Administration would improve access to fertility care, this new initiative will not make a meaningful difference toward removing the financial and systemic barriers our patients currently face. I sincerely hope our government can recognise that comprehensive fertility care is essential healthcare and take action seen as broadly popular among Americans to ensure those living in the USA have access to treatment should they need it build their families.